Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.64 |
| ▸ | KYNU | Q16719 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 5/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387860 | 1.00 | CTSK (0.64) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL527103 | 1.00 | CTSK (0.64) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL1643831 | 0.91 | CTSK (0.60) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL1643830 | 0.91 | CTSK (0.60) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL526571 | 0.91 | CTSK (0.60) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL28162782 | 0.91 | KYNU (0.60) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL5191992 | 0.91 | KYNU (0.60) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL16351361 | 0.90 | KYNU (0.62) | CTSKKYNUALDH1A1ALOX15CTSS | |
| SCHEMBL18075229 | 0.89 | CTSK (0.65) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL18075231 | 0.89 | CTSK (0.65) | CTSKCTSSCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829568-B1 | SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| EP-2598476-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | Indoco Remedies Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012014226-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-RE38551-E1 | ADMINISTERING N-BENZYL-2- ACETAMIDO PROPIONAMIDE DERIVATIVES IN THE R CONFIGURATION, SUCH AS LACOSAMIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| US-5773475-A | DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | CTSK 371/4885KYNU 1372/4885ALDH1A1 3776/4885 |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | CTSK 2162/4885KYNU 120/4885ALDH1A1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.